Nagpur: The RAPP Unit-8 project in Rajasthan has received regulatory approval for its First Approach to Criticality (FAC), marking a significant step towards commissioning India’s indigenously developed 700 MWe nuclear reactor.
The Atomic Energy Regulatory Board (AERB) granted the permission on November 19, 2026, after completing the requisite safety reviews.
The approval allows RAPP Unit-8, the eighth unit at the Rawatbhata Nuclear Power Plant site, to proceed to the next stage of reactor commissioning.
The FAC is an important milestone in which the reactor moves towards achieving a controlled nuclear chain reaction.
The clearance follows a comprehensive assessment of the reactor’s design, construction, commissioning test results and operational preparedness.
AERB’s review involved detailed evaluations by its safety review committees, regulatory inspections and deliberations by the Board.
The FAC approval does not mean that the reactor has started commercial electricity generation.
RAPP Unit-8 will have to complete subsequent commissioning activities and prescribed tests, along with obtaining further regulatory permissions, before moving towards commercial operations.
AERB will continue overseeing the commissioning process through safety assessments and regulatory inspections. Its resident site observer team will also monitor activities at the project site.
RAPP Unit-8 is India’s fourth 700 MWe Pressurised Heavy Water Reactor (PHWR) of an indigenous design developed and constructed in the country.
The other three reactors in this series are Kakrapar Atomic Power Station Units 3 and 4 in Gujarat and Rajasthan Atomic Power Project Unit-7.
Located at the Rawatbhata Nuclear Power Plant site in Rajasthan’s Chittorgarh district, RAPP Unit-8 is part of a nuclear facility that currently houses eight nuclear power plant units.
The latest regulatory clearance brings the reactor closer to completing its commissioning process, although commercial electricity generation remains subject to the successful completion of the remaining tests and regulatory approvals.





